Destiny Pharma plc

Bildquelle: Adobe Stock; © Tatiana Shepeleva

Destiny Pharma (LSE:DEST) is an established, late clinical stage biotechnology company developing medicines as novel approaches to the prevention of infectious diseases. Its diversified pipeline targets a broad range of indications and includes two Phase 3 clinical trial ready assets addressing areas of high unmet medical need as well as a range of earlier research programmes. Destiny’s most advanced programmes include XF-73, derived from Destiny’s proprietary XF Platform, for the prevention of post-surgical Staphylococcus aureus infections, and the biotherapeutic product NTCD-M3 for the prevention of recurring C. difficile gut infections, the leading cause of hospital acquired infection in the US.




Destiny at a glance:

Field of Activity Development of novel antimicrobials to prevent life-threatening infection, combat AMR and improve patient outcomes and healthcare costs.
Ownership Structure and Financing Public company listed since 2017 on LSE, raised over £50m equity plus over £3m in grants and non-diluting government funding.
Partners China Medical Systems have China rights and own 9% of the Company. Co-development of SPOR-COV with SporeGen as novel biotherapeutic to prevent COVID-19/influenza.
Technology XF Platform: proprietary porphyrin ring-based chemistry with novel resistance breaking MoA
NTCD-M3: naturally occurring non-toxigenic strain of C.difficile.
Products/Services Pipeline has novel biotherapeutics and XF-based drugs, including two assets targeting infection prevention that have successfully completed Phase 2 clinical trials and Phase 3 design parameters with FDA and EMA.
Unique Selling Point Diversified pipeline targeting biotherapeutic and drug-based infection prevention with low-cost anti-resistant medical products via easy administration routes.
Date of Incorporation/
Number of Employees
Founded 1997, 11-50


Contact :

Neil Clark, CEO
Address Sussex Innovation Centre
Science Park Square
Telephone +44 1273 704440
Web Address